| scholarly article | Q13442814 |
| P2093 | author name string | Hua Xiong | |
| Dan-Feng Sun | |||
| Jing-Yuan Fang | |||
| Xiao-Qing Tian | |||
| Yan-Jie Zhang | |||
| Shu-Liang Zhao | |||
| P2860 | cites work | TOR signaling in growth and metabolism | Q27860757 |
| mTOR and cancer therapy | Q28268516 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Q34531564 | ||
| The MAPK signalling pathways and colorectal cancer | Q36111490 | ||
| The Akt-mTOR tango and its relevance to cancer | Q36260264 | ||
| From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy | Q36352100 | ||
| New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. | Q36557283 | ||
| Therapeutic targets: MTOR and related pathways | Q36592032 | ||
| mTOR, translation initiation and cancer | Q36623679 | ||
| When translation meets transformation: the mTOR story | Q36623684 | ||
| Targeting mammalian target of rapamycin (mTOR) for health and diseases. | Q36727182 | ||
| Small molecule signal transduction inhibitors for the treatment of solid tumors | Q36895413 | ||
| PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway | Q38507712 | ||
| Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells | Q40001089 | ||
| Common effector processing mediates cell-specific responses to stimuli | Q40105919 | ||
| Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer | Q40164478 | ||
| Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells | Q40169850 | ||
| Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer | Q40194215 | ||
| Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway | Q40326784 | ||
| Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression | Q46868532 | ||
| Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. | Q47294305 | ||
| Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. | Q48352796 | ||
| P433 | issue | 3 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 273-285 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Cancer Investigation | Q325953 |
| P1476 | title | Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer | |
| P478 | volume | 27 |
| Q38966079 | A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells. |
| Q39458515 | Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway |
| Q42437883 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells |
| Q64111464 | Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma |
| Q35798540 | Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts |
| Q26781362 | Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers |
| Q39831242 | Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. |
| Q38081233 | Everolimus in colorectal cancer |
| Q35148085 | Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells |
| Q27851616 | KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. |
| Q35157985 | Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders |
| Q28074073 | Mechanisms of resistance to anti-EGFR therapy in colorectal cancer |
| Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
| Q90348651 | Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer |
| Q37349748 | Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. |
| Q33439312 | Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors |
| Q38014668 | Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations |
| Q91644121 | Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now? |
| Q38238743 | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer |
| Q53397945 | The Biological Activities of Oleocanthal from a Molecular Perspective. |
| Q38043507 | The promise of mTOR inhibitors in the treatment of colorectal cancer |
| Q84965476 | mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway |
| Q27851707 | mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors |
Search more.